Endocrine Abstracts

Introduction: The incidence and prevalence of GEP-NENs is rising worldwide. NENs represent the group off well differentiated neuroendocrine tumours (NET) and poorly differentiated neuroendocrine carcinoma (NEC). NETs can be divided into grade 1 (G1), grade 2 (G2) and grade 3 (G3) based on histological parameters. There exist several studies regarding survival data but these are mainly based on national databases.Aim: To describe the real world overall su...

Background: Small pancreatic neuroendocrine tumours (PNETs) present a management dilemma because of their uncertain natural history. Some clinicians believe that lesions <2 cm are indolent and can be managed with surveillance. By contrast, the most recent WHO classification system regards all PNETs as potentially malignant.Aim: To assess the malignant behaviour of small PNETs in a large, retrospective, multicentre patient cohort.<p class="abstext...

Background: The lack of relevant in-vivo and in-vitro models has precluded investigations of the pathophysiology of metastatic NENs. Organotypic tumour slices retain the complexity of tumours in-vivo without extensive manipulation of the tissue. The aims of this study are to understand the utility of precision cut slice technology to develop an immunocompetent model of metastatic GEP NENs to test new therapeutics and elucidate immunological, molecula...

Accumulating evidence suggests that the immunological landscape plays a key role in the progression of neuroendocrine liver metastases (LM-NENs), which is often characterised by immune cell infiltration. Anti-tumour functions of infiltrating lymphocytes are often silenced through hyper-expression of inhibitory checkpoint receptors (CRs) such as PD-1, but favourable outcomes with anti-PD-1 therapy have been low. Recently, functional soluble (cell-free) CRs beyond PD-1 have been...